Payton LeBlanc: Nanoparticle Enhanced, Impedance-Based Biosensor Development for Cancer Diagnosis

Payton LeBlanc presents on her research: Current research shows urinary metabolites can be classified as biomarkers for colon cancer. Colon cancer is primarily diagnosed with colonoscopies and blood tests: both of which are extremely invasive. It is our goal to develop a biosensor that uses nanoparticles bound with metabolites for normalization, to detect the presence of free metabolites in the urine samples of patients.